CAS 1032900-25-6: Ceritinib

Description: Ceritinib is a targeted therapy medication primarily used in the treatment of non-small cell lung cancer (NSCLC) that is characterized by anaplastic lymphoma kinase (ALK) gene rearrangements. It is classified as a kinase inhibitor, specifically designed to inhibit ALK and other related kinases, thereby disrupting cancer cell proliferation and survival. Ceritinib is administered orally and is known for its ability to penetrate the blood-brain barrier, making it effective against central nervous system metastases. The substance has a molecular formula that reflects its complex structure, which includes multiple functional groups that contribute to its pharmacological activity. Common side effects associated with ceritinib include gastrointestinal disturbances, liver enzyme elevations, and fatigue. Due to its mechanism of action, ceritinib is often considered for patients who have progressed on other ALK inhibitors, highlighting its role in personalized cancer therapy. As with any medication, monitoring for adverse effects and drug interactions is essential during treatment.

Formula: C₂₈H₃₆ClN₅O₃S

InChI: InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)

InChI key: InChIKey=VERWOWGGCGHDQE-UHFFFAOYSA-N

SMILES: O=S(=O)(C=1C=CC=CC1NC2=NC(=NC=C2Cl)NC=3C=C(C(=CC3OC(C)C)C4CCNCC4)C)C(C)C

Synonyms:

• 2,4-Pyrimidinediamine, 5-chloro-N⁴-[2-[(1-methylethyl)sulfonyl]phenyl]-N²-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-
• 5-Chloro-N4-(2-((1-Methylethyl)Sulfonyl)Phenyl)-N2-(5-Methyl-2-(1-Methylethoxy)-4-(4-Piperidinyl)Phenyl)-2,4-Pyrimidinediamine
• 5-Chloro-N⁴-[2-[(1-methylethyl)sulfonyl]phenyl]-N²-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine
• Ldk 378
• Ldk378
• Zykadia
• Ceritinib
• 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-

5-Chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine

CAS: 1032900-25-6

• Formula: C₂₈H₃₆ClN₅O₃S
• Purity: 98%
• Color and Shape: Solid
• Molecular weight: 558.1351

Ceritinib

CAS: 1032900-25-6

• Formula: C₂₈H₃₆ClN₅O₃S
• Color and Shape: White To Off-White Solid
• Molecular weight: 558.14

LDK378

CAS: 1032900-25-6

• Purity: 98%
• Molecular weight: 558.14g/mol

Ceritinib

CAS: 1032900-25-6

Ceritinib (LDK378) is an ALK inhibitor with selective, ATP-competitive, and oral activity. Ceritinib has antitumor …

• Formula: C₂₈H₃₆ClN₅O₃S
• Purity: 100% - 99.77%
• Color and Shape: Solid
• Molecular weight: 558.14

LDK378

CAS: 1032900-25-6

5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine

CAS: 1032900-25-6

Applications 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine, is a Anaplastic lymphoma kinase (ALK) inhibitor. References Marsilje, T. H., et al.: …

• Formula: C₂₈H₃₆ClN₅O₃S
• Color and Shape: Neat
• Molecular weight: 558.14

Ceritinib

CAS: 1032900-25-6

ALK receptor tyrosine kinase inhibitor

• Formula: C₂₈H₃₆ClN₅O₃S
• Purity: Min. 95%
• Color and Shape: Powder
• Molecular weight: 558.14 g/mol